Synovial fluid T cell clones from oligoarticular juvenile arthritis patients display a prevalent Th1/Th0-type pattern of cytokine secretion irrespective of immunophenotype

M. GATTORNO, P. FACCHETTI*, F. GHIOTTO*, S. VIGNOLA, A. BUONCOMPAGNI, I. PRIGIONE*, P. PICCO & V. PISTOIA* II Division of Pediatrics and *Laboratory of Oncology, 'G. Gaslini' Institute for Children, Genova, Italy

(Accepted for publication 27 March 1997)

SUMMARY

The aim of the present study was to investigate the patterns of cytokine production by T cell clones raised from in vivo activated synovial fluid (SF) mononuclear cells (MNC) of five patients with oligoarticular juvenile arthritis (JA). Freshly isolated SF T cells were cultured in vitro with low dose recombinant IL-2 and subsequently cloned by limiting dilution. Sixty-four clones were obtained from the five patients studied. Fifty-nine clones were TCR α/β^+ , either CD4⁺ (n = 43) or CD8⁺ (n = 15). The remaining five clones were TCR γ/δ^+ , CD4⁻, CD8⁻. Clone immunophenotypes differed in the individual patients. Forty-four T cell clones were stimulated with phytohaemagglutinin (PHA) and phorbol myristate acetate (PMA) and supernatants tested for the presence of IL-2, IL-4, IL-5 and interferon-gamma (IFN- γ) by ELISA or bioassays. Cytokine mRNA accumulation was tested by reverse transcriptase-polymerase chain reaction (RT-PCR). Most of 44 clones tested released large amounts of IFN- γ irrespective of the immunophenotype. Of these, 27 were classified as Th1-type and 17 as Th0type based upon the IFN- γ /IL-4 ratio in culture supernatants. Finally, when 10 representative T cell clones were tested for pro- and anti-inflammatory cytokines, gene expression by RT-PCR, all of them were found to express the granulocyte-macrophage colony-stimulating factor (GM-CSF), tumour necrosis factor-alpha (TNF- α), IL-10 and transforming growth factor-beta 1 (TGF- β 1) genes, and half of them IL-6 and IL-8 mRNA. In conclusion, T cell clones, that represent the progeny of in vivo activated SF T cells from oligoarticular JA patients, display heterogeneous immunophenotypes, but all share the ability to produce large amounts of IFN- γ , with a predominant Th1/Th0 pattern. The expression of pro- and anti-inflammatory cytokine genes in these clones suggests that in vivo activated SF T cells modulate joint inflammation in a complex fashion.

Keywords juvenile arthritis T cell clones Th1

INTRODUCTION

Oligoarticular juvenile arthritis (JA) is a peculiar entity in the group of rheumatic diseases of childhood. It is clinically characterized by the involvement of four joints or less, with a frequent positivity for serum antinuclear antibodies (ANA) and possible association with anterior uveitis [1].

The pathogenesis of JA is poorly understood. The finding that activated T cells are consistently detected in the synovial fluid or membrane of JA patients [2–6] may suggest that antigen-specific T lymphocytes [7–9] act as initiators of the inflammatory process.

Correspondence: Marco Gattorno, II Division of Pediatrics, 'G. Gaslini' Institute for Children, Largo G. Gaslini 5, 16147, Genova, Italy. Cytokines locally released by activated T cells may play a role in tissue damage [10].

Production of IL-2, IL-4, IL-5 and interferon-gamma (IFN- γ) allows one to identify two discrete subsets of CD4⁺ T cells, namely T helper (Th)1 and Th2, respectively [11–14]. Th1 cells produce IL-2 and IFN- γ , but little or no IL-4 or IL-5. Conversely, Th2 cells specialize in the production of IL-4 and IL-5, but not of IL-2 or IFN- γ . A third subpopulation of CD4⁺ cells, named Th0, displays an unrestricted profile of cytokine production [15,16]. Th0 cells may represent precursors of Th1 or Th2 cells [17]. In disease states characterized by accumulation of activated T cells, the patterns of cytokines produced can influence the pathophysiology of the underlying disease as well as its clinical manifestations.

The latter issue has been addressed in a few studies which have

shown a predominant Th1 pattern in synovial membrane [18–21] or fluid [19] T cells from rheumatoid arthritis (RA) patients. Virtually no information is available on the patterns of cytokine production by synovial T cells from children with JA, in particular with the oligoarticular subtype. Here we investigated the immunophenotype and the patterns of cytokine production of a panel of clones raised from IL-2-expanded synovial fluid (SF) T cells of five patients with oligoarticular JA.

PATIENTS AND METHODS

Patients

Five oligoarticular JA patients were studied. The diagnosis was established according to the new Classification Criteria for Idiopathic Arthritides of Childhood [1]. According to the above mentioned criteria, the oligoarthritis subgroup includes patients with idiopathic arthritis affecting one to four joints during the first 6 months of disease. Spondyloarthopathy or positive family history of spondyloarthopathy, rheumatoid factor and/or HLA-B27 positivity are specific exclusion criteria.

Four patients were female, one was male. Their ages ranged from 6 to 13 years. Disease duration ranged from 7 months to 2.9 years (Table 1). At study, no patient presented iridocyclitis.

Cell separation and culture

SF and peripheral blood mononuclear cells (PBMC) were separated by centrifugation on a Ficoll–Hypaque gradient and suspended in RPMI 1640 medium (Seromed Biochrom KG, Berlin, Germany) supplemented with L-glutamine, penicillin-streptomycin (Seromed) and 10% fetal calf serum (FCS; Seromed Biochrom KG) (complete medium). SF PBMC (1×10^6 /ml) were subsequently cultured in 24-well plates with 50 U/ml rIL-2 (Genzyme, Milan, Italy) in an atmosphere containing 5% CO₂ in air [22]. After 7 days in culture, lymphoid blasts were purified (>95%) on a Percoll (Pharmacia, Uppsala, Sweden) gradient, as previously reported [22] and cloned by limiting dilution (see below).

The cloning procedure was performed as follows. Percollenriched blast cells were seeded in 96-well U-bottomed plates at a concentration of 0.5–1 cell/well in 0.2 ml of complete medium supplemented with 50 U/ml rIL-2 in the presence of 10^5 gammairradiated (60 Gy) allogeneic PBMC and 0.5 µg/ml phytohaemagglutinin (PHA-P; Wellcome Burroughs, London, UK) [22]. Cells were fed weekly with fresh, complete medium containing 50 U/ml rIL-2. After 15–20 days each well was checked microscopically and proliferating microcultures were expanded in rIL-2-containing medium [22]. By this procedure, the cloning efficiency was approximately 15%. Cytokine production by SF-derived clones was investigated following non-specific stimulation. Cloned T cells were washed twice, resuspended at the concentration of 1×10^6 /ml in complete medium and cultured for 24–48 h with $1 \mu g$ /ml PHA-P plus 5 ng/ml phorbol myristate acetate (PMA; Sigma Chemical Co., St Louis, MO). Supernatants were collected and stored at -80° C until tested.

Immunophenotypic analyses

Surface marker analysis was performed on freshly isolated SF and PBMC and cultured lymphocytes (after 7 days) by direct immunofluorescence using a panel of FITC- or PE-conjugated murine MoAbs. Peripheral blood was obtained from five healthy donors (age range 5-15 years), following the informed consent of the parents. The following MoAbs were used: CD3, CD4 and CD8 from Dako (Glostrup, Denmark); HLA-DR and CD69 from Becton Dickinson (Mountain View, CA); CD20 and CD25 from Coulter (Hialeah, FL); CD16 from Serotec (Oxford, UK), Cells were incubated with saturating amounts of MoAbs for 30 min on ice, washed twice and analysed by a FACScan flow cytometer (Becton Dickinson) setting the gate on the lymphocyte population [23]. Both single and double staining experiments were carried out. Isotype-matched, fluorochrome-conjugated MoAbs of unrelated specificities were used as controls to assess the non-specific binding of test MoAbs to each cell preparation and to set the threshold between positively and negatively staining cell populations [23].

Cytokine detection in culture supernatants

IL-2 and IL-5 were detected by biological assays. IL-2 was measured according to the capacity of the culture supernatants to promote the proliferation of the IL-2-dependent CTLL-2 murine cell line [24]. IL-5 was detected by the same principle using the murine LyH7.B13 target cell line, kindly donated by Dr Ronald Palacios [25]. For both cytokines, the amounts contained in test supernatants were quantified by comparison with the dose–response curves obtained by culturing the two cell lines with different concentrations of human rIL-2 or rIL-5 (Genzyme), respectively. IFN- γ and IL-4 were assayed using ELISA kits from Genzyme. The minimum threshold of detection of these assays is 100 pg/ml for IFN- γ and 45 pg/ml for IL-4.

T cell clones were subdivided into three groups based upon the IFN- γ /IL-4 ratio, calculated by dividing the concentrations of the two cytokines detected in clone supernatants [13,26]. An IFN- γ /IL-4 ratio ranging from 0·1 to 10 was taken as evidence for Th0-type of clones; when the same ratio was >10 or <0·1, the clones

Table 1. Clinical characteristics of oligoarticular juvenile arthritis (JA) patients and treatment at the time of synovial fluid aspiration

Patient	Sex	Age at onset, years	Duration of disease	Duration of arthritic flare-up, days	ANA	IgM RF	HLA-B27	Treatment
A	F	6	8 months	32	+	_	_	NSAID
В	F	10	1 year	15	+	_	_	_
С	М	11	7 months	13	+	_	_	_
D	F	13	2.9 years	37	+	_	_	NSAID
E	F	8	1.8 years	24	+	_	_	NSAID

ANA, Antinuclear antibodies; RF, rheumatoid factor; NSAID, non-steroidal anti-inflammatory drug.

were defined as Th1-type or Th2-type, respectively. High levels in culture supernatants of either IL-4 or IFN- γ *per se* were not considered as sufficient criteria for the definition of the Th2- or Th1-type pattern, respectively.

Detection of cytokine mRNA by reverse transciptase-polymerase chain reaction

The expression of IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IFN-7, transforming growth factor-beta 1 (TGF- β 1) and granulocytemacrophage colony-stimulating factor (GM-CSF) genes was investigated using the reverse transcriptase-polymerase chain reaction (RT-PCR) procedure. Total RNA was extracted from 10^6 cloned T cells that had been cultured for 6 h with $1 \,\mu \text{g/ml}$ PHA-P and 5 ng/ml PMA. RNA was extracted by a modified Chomczynsky-Sacchi method [27] and reverse-transcribed into cDNA for PCR amplification using the 1st strand cDNA Synthesis Kit (Clontech Labs Inc., Palo Alto, CA) and the oligo dT primer supplied with the kit according to the instructions of the manufacturer. The resulting cDNA mixture was diluted to a final volume of 100 μ l and 3 μ l were amplified with forward and reverse primers specific for the glyceraldehyde-3-phosphate dehydrogenase (G3PDH) housekeeping gene to check the efficiency of reverse transcription. Forward (F) and reverse (R) primers specific for IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IFN- γ , TGF- β 1 and GM-CSF genes were: IL-2 F ACTCACCAGGATGCTCACAT, IL-2 R AGGTAA-TCCATCTGTTCAGA; IL-4 F CCGAGTTGACCGTAACAGAC, IL-4 R TTCCTGTCGAGCCGTTTCAG; IL-5 F GAAATTCCCA-CAAGTGCATTG, IL-5 R CTATTATCCACTCGGTGTTCA; IL-6 F ATGTAGCCGCCCCACACAGA, IL-6 R CATCCATCTTTT-CAGCCAT [28]; IL-8 F CAGCCTTCCTGATTTCTGCA, IL-8 R CCCTCTGCACCCAGTTTTCC; IL-10 F ATGCCCCAAGCT-GAGAACCAAGACCCA, IL-10 R TCTCAAGGGGCTGGGT-CAGCTATCCCA; IFN-y F ATGCAGGTCATTCAGATGTAG, IFN-γ R GTCAGTTACCGAATAATTAGTC; TGF-β1 F GCCC-TGGACACCAACTATTGC, TGF-β1 R GCAGGAGCGCACGA-TCATGT; GM-CSF F ATCTCTGCACCCGCCCGCTCG, GM-CSF R CCCTGCTTGTACAGCTCCAGG. Three microlitres of the cDNA mixture for each sample were amplified using 25 pmoles of each cytokine-specific primer and 2U of Taq polymerase (Boehringer, Mannheim, Germany) by 35 cycles of denaturation of 94°C for 1 min, annealing and extension at 55°C (IL-2, IL-6), 62°C (IFN-γ) and 70°C (IL-10, GM-CSF) for 2 min; denaturation of 94°C for 1 min, annealing at 60°C (IL-4, IL-5, IL-8) for 1 min or 65° C (TGF- β 1) and extension at 72°C for 1 min in a total volume of 50 ml. PCR products were analysed by electrophoresis on 2% agarose gel and visualized by ethidium bromide staining.

RESULTS

Establishment and characterization of T cell clones from IL-2-expanded SF PBMC

PBMC were isolated from the SF of the five children with oligoarticular JA, stained with MoAbs and analysed by flow cytometry. Lymphocytes comprised predominantly CD3⁺, TCR α/β^+ cells, with a CD4/CD8 ratio ranging from 0.79 to 1.6. TCR γ/δ^+ cells and natural killer (NK) (CD16⁺) cells were also detected (ranges 3–11% and 6–18%, respectively) (not shown and [4]).

Double staining experiments showed that approximately one third of the T lymphocytes from all SF samples expressed the CD69 and/or HLA-DR activation markers, whereas CD25 was detected on a minor T cell fraction only (Fig. 1). These markers



Fig. 1. Expression of activation markers (HLA-DR, CD25 and CD69) on freshly isolated synovial fluid (SF) T cells from five patients with oligoarticular juvenile arthritis. \blacklozenge , Patient A; \blacktriangle , patient B; \blacklozenge , patient C; \blacksquare , patient D; \blacktriangledown , patient E.

were found on both CD4⁺ and CD8⁺ lymphocytes (not shown and [29]).

Immunophenotypic studies carried out with paired peripheral blood samples from the five patients showed no increase in the proportion of CD69⁺, CD25⁺ or HLA-DR⁺ T cells compared with normal, age-matched controls.

In subsequent experiments, SF PBMC were cultured for 7 days with low-dose rIL-2, enriched for blasts by a Percoll density gradient and cloned by limiting dilution. This procedure was selected with the aim of expanding and cloning *in vitro* those lymphocytes that were already activated *in vivo*. Sixty-four clones were obtained from the five SF samples; 44 T cell clones were TCR α/β^+ , CD4⁺, 15 were TCR α/β^+ , CD8⁺ and the remaining five were TCR γ/δ^+ , CD4⁻, CD8⁻.

Cytokine production by T cell clones derived from in vivo *activated SF T cells*

In order to investigate cytokine secretion by SF PBMC-derived T cell clones, cells from 44/64 clones (29 CD4⁺, 10 CD8⁺ and five TCR γ/δ^+ , CD4⁻, CD8⁻, Table 2) were stimulated with PHA and PMA for 24–48 h and supernatants tested for the presence of IFN- γ , IL-2, IL-4 and IL-5 using immuno- or bioassays. These cytokines were selected for study since their production helps to delineate the Th1, Th2 or Th0 profiles of cytokine secretion [11–17].

As shown in Table 2, most of the clones produced high amounts of IFN- γ irrespective of the immunophenotype. In contrast, only six clones, all of which were CD4⁺, released IL-5 (Table 2). IL-2 was detected in variable amounts in the supernatants of 19 clones; 13 of them were CD4⁺, four CD8⁺ and two TCR γ/δ^+ (Table 2). IL-4 was released by 23 T cell clones; 19 of them were CD4⁺, three CD8⁺ and one TCR γ/δ^+ (Table 2).

Taken together, these results suggest that the major feature of SF-derived T cell clones was IFN- γ production, whereas IL-2 and IL-4 were released predominantly by subsets of CD4⁺ clones and IL-5 was detected only occasionally.

 Table 2. Cytokine production by synovial fluid (SF)-derived T cell clones after phorbol myristate acetate (PMA)-phytohaemagglutinin (PHA) stimulation

Partient A Partient A 1 CD8 3670 2 80 0 Th1 2 CD8 3560 0 0 0 Th1 3 CD8 700 0 0 0 Th1 4 CD4 1110 0 1000 0 Th1 4 CD4 700 0 0 0 Th1 6 CD4 5200 0 1150 0 Th0 Parient B 7 CD4 1600 12 70 100 Th1 8 CD4 3000 0 160 120 Th1 9 CD4 4600 ND 2100 ND Th0 11 CD8 5200 2 2600 ND Th0 12 CD4 3600 0 1450 80 Th0 13 CD4 3600 2 0 ND Th1	Clones	Phenotype	IFN-γ (pg/ml)	IL-2 (U/ml)	IL-4 (pg/ml)	IL-5 (pg/ml)	Pattern
1 CD8 3670 2 80 0 Thi 2 CD8 3600 0 0 0 Thi 3 CD8 700 0 0 0 Thi 4 CD4 1110 0 100 0 Thi 5 CD4 200 0 0 Thi Thi 6 CD4 3000 0 0 ND Thi 8 CD4 3000 0 160 ND Thi 9 CD4 4600 ND 2100 ND Thi 10 CD4 3600 0 1600 D Thi 11 CD8 5200 2 2600 ND Thi 12 CD4 3800 0 1480 600 Thi 14 CD4 3800 2 0 ND Thi 15 CD4 3800 20 0<	Patient A						
2CD835600000Thi3CD8700000Thi4CD4111001000Thi5CD4700000Thi6CD45200011500Thi7CD41660127000Thi9CD43000000NDThi9CD434000160120Thi11CD8520022600NDTho12CD43600016000Tho13CD44300223000Thi14CD4360001000Thi15CD4360020NDThi16CD4360020NDThi18CD4370067000Thi18CD43700000Thi19CD80000Thi21CD436001650200Thi22CD831002700Thi23CD4500000Thi24CD42600501650200Thi25CD83260400Thi26CD43000000Thi <td>1</td> <td>CD8</td> <td>3670</td> <td>2</td> <td>80</td> <td>0</td> <td>Th1</td>	1	CD8	3670	2	80	0	Th1
3CD87000000Thi4CD411001000Thi6CD4520001500Th0Patient B7CD416001270100Th19CD44600ND2100NDTh19CD4340001660120Th111CD8520022600NDTh012CD43800016000Th013CD44300223000Th014CD4380001480600Th116CD4380001880600Th117 $\gamma \delta$ 50020NDTh116CD4880501480600Th017 $\gamma \delta$ 50020NDTh118CD4370067000Th123CD4510001650200Th024CD42500501650200Th025CD83260400Th126CD4510000Th127CD435001000Th128CD450000Th129CD8000Th133CD455000Th1<	2	CD8	3560	0	0	0	Th1
4CD4111001000Thi5CD47000000Thi $Patient B$ Tho7CD416001200NDThi9CD44600ND2100NDThi9CD444000160120Thi11CD8520022600NDThi12CD43800016000Thi13CD443000145080Thi14CD4380001000Thi15CD4380001000Thi16CD4430020NDThi18CD4370020NDThi18CD4380001000Thi18CD42000500Thi20CD44100018500Thi21CD831002700Thi22CD831002700Thi23CD452001650200Thi24CD4420000Thi25CD83260000Thi33CD4530000Thi34762500000Thi <td>3</td> <td>CD8</td> <td>700</td> <td>0</td> <td>0</td> <td>0</td> <td>Th1</td>	3	CD8	700	0	0	0	Th1
5 CD4 700 0 0 0 Thi 6 CD4 5200 0 1150 0 Thi 7 CD4 1600 12 70 100 Thi 9 CD4 4000 ND 2100 ND Thi 9 CD4 3400 0 160 120 Thi 10 CD4 3400 0 1650 80 Tho 11 CD8 5200 2 2600 ND Tho 13 CD4 3800 0 1650 80 Tho 14 CD4 3800 2 2300 0 Thi 16 CD4 3800 2 0 ND Thi 16 CD4 3700 6 700 0 Thi 17 γδ 500 2 70 0 Thi 16 CD4 3700 0	4	CD4	1110	0	100	0	Th1
6 CD4 S200 0 1150 0 Tho Patient B - - - 0 00 Tho Thi 8 CD4 3000 0 0 ND Thi 9 CD4 4600 ND 2100 ND Thi 11 CD8 S200 2 2600 ND Thi 11 CD4 3800 0 1600 0 Thi 12 CD4 3800 0 1600 0 Thi 13 CD4 3800 0 100 0 Thi 16 CD4 3800 0 100 0 Thi 18 CD4 3700 6 700 0 Thi 18 CD4 3700 0 150 0 Thi 12 CD4 4100 0 1850 0 Thi 12 CD4 100	5	CD4	700	0	0	0	Th1
Patient B 7 CD4 1600 12 70 100 Th1 9 CD4 4600 ND 2100 ND Th1 9 CD4 4600 ND 2100 ND Th1 11 CD8 5200 2 2600 ND Th1 12 CD4 3800 0 1600 0 Th1 13 CD4 4300 0 1450 80 Th0 14 CD4 3800 0 1000 0 Th1 16 CD4 3800 2 0 ND Th1 16 CD4 3700 6 70 0 Th1 18 CD4 3700 6 70 0 Th1 18 CD4 200 0 1850 0 Th0 21 CD4 200 0 1850 0 Th1 22 CD8<	6	CD4	5200	0	1150	0	Th0
7CD416001270100Th18CD4300000NDTh19CD44600ND2100NDTh010CD434000160120Th111CD8520022660NDTh012CD438000145080Th013CD44300223000Th014CD4380001000Th116CD4380001000Th118CD4370067000Th118CD4370067000Th118CD43700018500Th020CD44100018500Th021CD831002700Th122CD831002700Th123CD4250010000Th124CD42600501650200Th125CD83260400Th126CD43100000Th127CD4350010000Th128CD43100000Th133CD4530000Th134CD4650000Th1	Patient B						
8CD43000000NDTh09CD44600ND2100NDTh010CD43400016000Th011CD8520022600NDTh012CD443000145080Th013CD443000145080Th014CD4380001000Th116CD4850501480600Th017 $\gamma \delta$ 50020NDTh118CD4370067000Th020CD4410008500Th021CD42000500Th123CD45100021500Th124CD42600501650200Th125CD83100000Th126CD44200400Th127CD45200000Th123CD80000Th133CD4580000Th134CD46800000Th135CD411002000Th136 $\gamma \delta$ 3650000Th136 $\gamma \delta$ 3650000<	7	CD4	1600	12	70	100	Th1
9CD44600ND2100NDTh010CD434000160120Th111CD8520022600NDTh012CD438000145080Th013CD44400223000Th015CD4380001000Th116CD4850501480600Th118CD450020NDTh118CD4300000Th119CD80000-20CD44100018500Th021CD42000500Th022CD831002700Th123CD45001650200Th124CD42600501650200Th125CD83260400Th126CD4430000Th127CD4350010000Th128CD8000Th131 $\gamma\delta$ 43500400Th132CD8360000Th133CD465000Th134CD465000Th135CD465000	8	CD4	3000	0	0	ND	Th1
10CD434000160120Th111CD8520022600NDTh012CD438000145080Th013CD44300223000Th114CD4380001000Th116CD4850501480660Th017 $\gamma \delta$ 50020NDTh118CD4370067000Th020CD44100018500Th021CD42000500Th022CD831002700Th123CD45100021500Th124CD42600501650200Th025CD83260400Th126CD44300000Th127CD8300000Th128CD43100000Th133CD45300000Th134CD46800221000Th135CD4650000Th136 $\gamma \delta$ 3650000Th136 $\gamma \delta$ 3650000Th136 $\gamma \delta$ 3650000Th1	9	CD4	4600	ND	2100	ND	Th0
11CD8520022600NDTho12CD43800016000Tho13CD44300223000Tho14CD4380001000Th115CD4380001000Th116CD4850501480600Th017 $\gamma \delta$ 50020NDTh118CD4370067000Th0Pattent C18500Th020CD44100018500Th021CD4200021500Th123CD45100021500Th124CD42600501650200Th025CD83260400Th126CD44300000Th127CD4350010000Th133CD45470000Th134CD45800221000Th135CD415001000Th136 $\gamma \delta$ 3650000Th134CD4560000Th135CD415001000Th136 $\gamma \delta$ 3650000Th1<	10	CD4	3400	0	160	120	Th1
12 CD4 3800 0 1600 0 Tho 13 CD4 4300 0 1450 80 Tho 14 CD4 3400 2 2300 0 Thi 16 CD4 850 50 1480 600 Tho 16 CD4 850 50 1480 600 Tho 17 $\gamma \delta$ 500 2 0 ND Thi 18 CD4 3700 6 700 0 Tho 20 CD4 4100 0 1850 0 Tho 21 CD4 200 0 50 0 Tho 22 CD8 3100 2 70 0 Thi 23 CD4 5100 0 2150 0 Thi 24 CD4 2600 50 1650 200 Thi 26 CD4 3500 10	11	CD8	5200	2	2600	ND	Th0
13 CD4 4300 0 1450 80 Th0 14 CD4 3400 2 2300 0 Th0 15 CD4 3800 0 100 0 Th1 16 CD4 850 50 1480 600 Th0 17 $\gamma \delta$ 500 2 0 ND Th1 18 CD4 3700 6 700 0 Th0 20 CD4 4100 0 1850 0 To 21 CD4 200 0 50 0 Th1 23 CD4 5100 0 2150 0 Th1 23 CD4 5000 50 1650 200 Th1 24 CD4 2600 50 1650 200 Th1 25 CD8 3260 4 0 0 Th1 26 CD4 3100 0 <td>12</td> <td>CD4</td> <td>3800</td> <td>0</td> <td>1600</td> <td>0</td> <td>Th0</td>	12	CD4	3800	0	1600	0	Th0
14 CD4 3400 2 2300 0 Th0 15 CD4 3800 0 100 0 Th1 16 CD4 850 50 1480 600 Th0 16 CD4 3700 6 700 0 Th1 18 CD4 3700 6 700 0 Th1 18 CD4 3700 6 700 0 Th0 Patient C 0 0 0 - 20 CD4 4100 0 1850 0 Th0 21 CD4 200 0 50 0 Th1 23 CD4 5100 0 2150 0 Th1 23 CD4 2600 50 1650 200 Th1 24 CD4 2600 4 0 0 Th1 25 CD8 3260	13	CD4	4300	0	1450	80	Th0
15CD4380001000Th116CD4850501480600Th017 $\gamma \delta$ 50020NDTh118CD4370067000Th0Patient C19CD8000-20CD44100018500Th021CD42000500Th022CD831002700Th123CD45100021500Th024CD42600501650200Th126CD44200400Th127CD4350010000Th126CD44200400Th127CD4350010000Th128CD43100000Th133CD45470000Th134CD4650000Th135CD415001000Th136 $\gamma \delta$ 3650000Th137CD45501000Th138CD4650000Th134CD4650000Th135CD4150010200 <td>14</td> <td>CD4</td> <td>3400</td> <td>2</td> <td>2300</td> <td>0</td> <td>Th0</td>	14	CD4	3400	2	2300	0	Th0
15 15 16 16 16 16 16 17 $\gamma \delta$ 500 2 0 ND Thi 17 $\gamma \delta$ 500 2 0 ND Thi 18 CD4 3700 6 700 0 Thi 18 CD4 3700 6 700 0 Thi 19 CD8 0 0 0 0 - 20 CD4 4100 0 1850 0 Thi 21 CD4 200 0 50 0 Thi 23 CD4 5100 0 2150 0 Thi 24 CD4 2600 50 1650 200 Thi 24 CD4 3260 4 0 0 Thi 25 CD8 3260 100 0 Thi Thi 26 CD4 3100 0 0 Th	15	CD4	3800	0	100	Ő	Th0 Th1
161616016016016016016017117 $\gamma \delta$ 50020NDTh118CD4370067000Th0Patient C </td <td>16</td> <td>CD4</td> <td>850</td> <td>50</td> <td>1480</td> <td>600</td> <td>Th0</td>	16	CD4	850	50	1480	600	Th0
11161602017017118CD4370067000Th0Patient C </td <td>17</td> <td>2D4 270</td> <td>500</td> <td>2</td> <td>0</td> <td>ND</td> <td>Th1</td>	17	2D4 270	500	2	0	ND	Th1
Instruct Instruct <thinstruct< th=""> <th< td=""><td>18</td><td>γ0 CD4</td><td>3700</td><td>6</td><td>700</td><td>0</td><td>Th0</td></th<></thinstruct<>	18	γ0 CD4	3700	6	700	0	Th0
Participation of the second system of the s	Pationt C	CD4	5700	0	700	0	1110
15CDS160180017020CD44100018500Th021CD42000500Th123CD45100021500Th024CD42600501650200Th125CD83260400Th126CD44200400Th127CD4350010000Th128CD43100000Th129CD80000Th131 $\gamma\delta$ 43500400Th132CD83800000Th133CD45470000Th134CD46800221000Th135CD415001000Th136 $\gamma\delta$ 3650000Th136 $\gamma\delta$ 3650000Th137CD4110020000Th139CD4650000Th141CD4660015000Th143 $\gamma\delta$ 3800200Th143 $\gamma\delta$ 3800200Th143 $\gamma\delta$ 3800200Th143<	10	CD8	0	0	0	0	_
20CD44100016300110021CD42000500Th022CD831002700Th123CD45100021500Th024CD42600501650200Th025CD83260400Th126CD44200400Th127CD4350010000Th128CD43100000-30 $\gamma\delta$ 2500000Th131 $\gamma\delta$ 43500400Th132CD83800000Th133CD45470000Th134CD46800221000Th135CD415001000Th136 $\gamma\delta$ 3650000Th137CD415001000Th139CD46201200Th140CD82600015000Th141CD43600102700Th143 $\gamma\delta$ 3800200Th143 $\gamma\delta$ 3800200Th143 $\gamma\delta$ 3800200Th1	20	CD4	4100	0	1850	0	ThO
21 $CD4$ 200 0 30 0 110 22 $CD8$ 3100 2 70 0 $Th1$ 23 $CD4$ 5100 0 2150 0 $Th0$ 24 $CD4$ 2600 50 1650 200 $Th0$ 25 $CD8$ 3260 4 0 0 $Th1$ 26 $CD4$ 4200 4 0 0 $Th1$ 27 $CD4$ 3500 100 0 0 $Th1$ 27 $CD4$ 3100 0 0 0 $ 28$ $CD4$ 3100 0 0 0 $ 29$ $CD8$ 0 0 0 0 $ 30$ $\gamma\delta$ 2500 0 0 0 $ 31$ $\gamma\delta$ 4350 0 40 0 $Th1$ 31 $\gamma\delta$ 4350 0 0 0 $Th1$ 33 $CD4$ 5470 0 0 0 $Th1$ 34 $CD4$ 6800 2 2100 0 $Th1$ 34 $CD4$ 650 0 0 0 $Th1$ 36 $\gamma\delta$ 3600 0 0 $Th1$ 38 $CD4$ 650 0 0 0 $Th1$ 40 $CD8$ 2600 0 0 $Th1$ 41 $CD4$ 3600 10 270 0 $Th1$ 43 $\gamma\delta$ 3800	20	CD4	200	0	50	0	Th0
22 $CD3$ 5100 2 70 0 111 23 $CD4$ 5100 0 2150 0 $Th0$ 24 $CD4$ 2600 50 1650 200 $Th0$ 25 $CD8$ 3260 4 0 0 $Th1$ 26 $CD4$ 4200 4 0 0 $Th1$ 27 $CD4$ 3500 100 0 0 $Th1$ 27 $CD4$ 3100 0 0 0 $Th1$ 29 $CD8$ 0 0 0 0 $ 30$ $\gamma\delta$ 2500 0 0 0 $ 30$ $\gamma\delta$ 2500 0 0 0 $ 31$ $\gamma\delta$ 3800 0 0 0 $Th1$ 31 $\gamma\delta$ 3800 0 0 0 $Th1$ 33 $CD4$ 5470 0 0 0 $Th1$ 34 $CD4$ 6800 2 2100 0 $Th1$ 34 $CD4$ 650 0 0 0 $Th1$ 36 $\gamma\delta$ 3650 0 0 0 $Th1$ 36 $\gamma\delta$ 3600 0 0 $Th1$ 38 $CD4$ 650 0 0 0 $Th1$ 40 $CD8$ 2600 0 0 $Th1$ 41 $CD4$ 3600 10 270 0 $Th1$ 43 $\gamma\delta$ 3800	21	CD4 CD8	3100	2	50 70	0	Th0 Th1
23CD410001050110024CD42600501650200Th025CD83260400Th126CD44200400Th127CD4350010000Th128CD43100000-30 $\gamma\delta$ 2500000-30 $\gamma\delta$ 2500000Th131 $\gamma\delta$ 43500400Th132CD83800000Th133CD45470000Th134CD46800221000Th135CD415001000Th136 $\gamma\delta$ 3650000Th138CD465000Th139CD46201200Th140CD43600015000Th141CD43600102700Th143 $\gamma\delta$ 3800200Th144CD43600102700Th144CD43600102700Th1452001500250Th14502001500	22	CD4	5100	0	2150	0	Th0
24CD42000301000200110025CD83260400Th126CD44200400Th127CD43500100000Th1Patient D28CD43100000-30 $\gamma \delta$ 2500000-31 $\gamma \delta$ 43500400Th132CD83800000Th133CD45470000Th134CD46800221000Th135CD415001000Th136 $\gamma \delta$ 3650000Th138CD46201200Th139CD46201200Th140CD8260000Th141CD43600015000Th143 $\gamma \delta$ 3800200Th143 $\gamma \delta$ 3800200Th14445002001500250Th1	23	CD4	2600	50	1650	200	ThO
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	24	CD4 CD8	2000		1050	200	Th0 Th1
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	25	CD4	4200	4	0	0	Th1
27 $CD4$ 300 100 0 0 0 111 $Patient D$ 28 $CD4$ 3100 0 0 0 0 111 29 $CD8$ 0 0 0 0 0 $ 30$ $\gamma\delta$ 2500 0 0 0 $ 31$ $\gamma\delta$ 4350 0 40 0 $Th1$ 31 $\gamma\delta$ 4350 0 40 0 $Th1$ 32 $CD8$ 3800 0 0 0 $Th1$ 34 $CD4$ 5470 0 0 0 $Th1$ 34 $CD4$ 6800 2 2100 0 $Th1$ 36 $\gamma\delta$ 3650 0 0 0 $Th1$ 36 $\gamma\delta$ 3650 0 0 0 $Th1$ 7 $CD4$ 1100 200 0 0 $Th1$ 7 $CD4$ 650 0 0 0 $Th1$ 39 $CD4$ 620 12 0 0 $Th1$ 40 $CD8$ 2600 0 0 $Th1$ 41 $CD4$ 3600 10 270 0 $Th1$ 43 $\gamma\delta$ 3800 2 0 0 $Th1$ 43 $\gamma\delta$ 3800 200 1500 250 $Th1$	20	CD4 CD4	4200	4	0	0	Th1
Pattern D28CD4 3100 000Th129CD80000-30 $\gamma\delta$ 2500000Th131 $\gamma\delta$ 43500400Th132CD83800000Th133CD45470000Th134CD46800221000Th136 $\gamma\delta$ 3650000Th136 $\gamma\delta$ 3650000Th1Patient E37CD4110020000Th139CD46201200Th140CD82600015000Th141CD43600102700Th143 $\gamma\delta$ 3800200Th143 $\gamma\delta$ 3800201500250Th1	21 Dationt D	CD4	5500	100	0	0	1111
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	r u u e n D	CD4	2100	0	0	0	Th 1
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	20	CD4 CD ⁹	5100	0	0	0	1111
30 $\gamma \delta$ 2500 0 0 0 0 111 31 $\gamma \delta$ 4350 0 40 0 Th1 32 CD8 3800 0 0 0 0 33 CD4 5470 0 0 0 Th1 34 CD4 6800 2 2100 0 Th1 34 CD4 6800 2 2100 0 Th1 36 $\gamma \delta$ 3650 0 0 0 Th1 36 $\gamma \delta$ 3650 0 0 0 Th1 36 $\gamma \delta$ 3650 0 0 0 Th1 36 $CD4$ 1100 200 0 0 Th1 38 CD4 650 0 0 0 Th1 39 CD4 620 12 0 0 Th1 41 CD4 3600 0 1500 0 Th1 41 CD4 3600 10 270 0 Th1 43 $\gamma \delta$ 3800 2 0 0 Th1 43 $\gamma \delta$ 3800 200 1500 250 Th1 44 $CD4$ 4500 200 1500 250 Th1	29	CDo	2500	0	0	0	— Th 1
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	21	γ0 	2300	0	0	0	1111 Th 1
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	22	γ_0	4550	0	40	0	1111 Th 1
35CD4 $34/0$ 0000011134CD4 6800 2 2100 0Th035CD4 1500 1000Th136 $\gamma\delta$ 3650 000Th1Patient E37CD4 1100 200 00Th138CD4 650 000Th139CD4 620 1200Th140CD8 2600 015000Th141CD4 3600 10 270 0Th143 $\gamma\delta$ 3800 200Th144CD4 4500 200 1500 250 Th1	32	CD8	5600	0	0	0	1 II I Th 1
34 $CD4$ 6800 2 2100 0 10 35 $CD4$ 1500 10 0 0 $Th1$ 36 $\gamma\delta$ 3650 0 0 0 0 $Th1$ Patient E	33	CD4 CD4	5470	0	2100	0	111 TLO
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	34	CD4 CD4	6800	2	2100	0	1 n0 Th 1
36 γo 3650 0 0 0 0 111 Patient E 37 CD4 1100 200 0 0 0 38 CD4 650 0 0 0 0 39 CD4 620 12 0 0 $Th1$ 40 CD8 2600 0 0 0 $Th1$ 41 CD4 3600 0 1500 0 $Th1$ 43 $\gamma \delta$ 3800 2 0 0 $Th1$ 44 CD4 4500 200 1500 250 $Th1$	35	CD4	1500	10	0	0	
Patient E37CD4110020000Th138CD4650000Th139CD46201200Th140CD82600000Th141CD43600015000Th042CD43600102700Th143γδ3800200Th144CD445002001500250Th0	36	$\gamma \delta$	3650	0	0	0	ThI
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Patient E		1100	200	0	0	T 1
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	37	CD4	1100	200	0	0	Thi
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	38	CD4	650	0	0	0	ThI
40CD826000000Th141CD43600015000Th042CD43600102700Th143 $\gamma\delta$ 3800200Th144CD445002001500250Th0	<u>59</u>	CD4	620	12	0	0	Thl
41CD4 3600 0 1500 0Th042CD4 3600 10 270 0Th143 $\gamma\delta$ 3800 200Th144CD4 4500 200 1500 250 Th0	40	CD8	2600	0	0	0	Th1
42CD4 3600 10 270 0Th143 $\gamma\delta$ 3800 200Th144CD4 4500 200 1500 250 Th0	41	CD4	3600	0	1500	0	Th0
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	42	CD4	3600	10	270	0	Th1
44 CD4 4500 200 1500 250 Th0	43	γδ	3800	2	0	0	Thl
	44	CD4	4500	200	1500	250	Th0

Nineteen of 44 clones were classified as Th1, since they produced IFN- γ , but not at all IL-4 (Table 2); of these, 10 were CD4⁺, five were CD8⁺ and four were TCR γ/δ^+ , CD4⁻, CD8⁻.

an IFN- γ /IL-4 ratio >10. In Fig. 2, a recapitulative subdivision of Th1- and Th0-type clones according their immunophenotype is shown.

Twenty-three of 44 clones released IFN- γ , IL-2, IL-4 and IL-5 in variable amounts; eight of such clones, five CD4⁺, two CD8⁺ and one TCR γ/δ^+ (clone nos 1, 4, 7, 10, 15, 22, 31 and 42 of Table 2) were operationally classified as Th1-type based upon

Altogether, 27 out of 44 clones displayed a Th1-type profile of cytokine production, whereas the remaining clones had a Th0-type pattern, as indicated by the IFN- γ /IL-4 ratio <10 (Table 2 and Fig. 2).



Fig. 2. Subdivision of the Th1- and Th0-type clones according to their immunophenotype. The CD4⁻ CD8⁻ clones were all TCR γ/δ^+ , as shown by staining with the specific MoAb (see Results). \Box , Total; \boxtimes , CD4⁺; \boxtimes , CD8⁺; \blacksquare , CD4⁻ CD8⁻.

Two of 44 clones (clones 19 and 29 of Table 2) did not secrete any of the four cytokines tested.

In subsequent experiments, 10 representative T cell clones, six $CD4^+$ and four $CD8^+$, were tested by RT-PCR for the expression of the IFN- γ , IL-2, IL-4 and IL-5 genes (Table 3) in order to investigate the relationships between the accumulation of cytokine mRNA and the presence of the corresponding proteins in T cell clone supernatants. These clones included the two which did not secrete appreciable amounts of any cytokine (see above, clones 19 and 29 of Table 2).

As shown in Table 3, 10/10 clones expressed IFN- γ mRNA, 8/10 displayed IL-2 transcripts, 7/10 expressed the IL-4 gene and only 2/10 were positive for IL-5 mRNA. When these results were compared with those of the assays with clone supernatants, a good correspondence between mRNA and protein production was found for each cytokine (Table 3). The only exceptions were: two clones that expressed IFN- γ mRNA but did not release the corresponding protein; three clones that expressed IL-2 mRNA but did not secrete the protein; one clone that was IL-4 mRNA⁺ but did not produce the protein (Table 3). It is of note that 8/10 clones tested were negative for the production of IL-5 mRNA and protein (Table 3).

Finally, the two clones which did not produce detectable cytokines in culture supernatants (see above) were found to express the IFN- γ , but not the IL-4 or IL-5 genes; the IL-2 gene was expressed in one clone only (Table 3, clone 29).

Expression of pro- and anti-inflammatory cytokine genes

Rheumatoid synovitis is characterized by the local release of numerous cytokines from different cell types, such as, for example, macrophages and synoviocytes. Therefore it was of interest to investigate whether cloned T cells could express the genes encoding a panel of proinflammatory and anti-inflammatory cytokines. To this end, 10 representative T cell clones (seven CD4⁺, two CD8⁺, one TCR γ/δ^+ , CD4⁻, CD8⁻), eight of which had already been tested for IFN- γ , IL-2, IL-4 and IL-5 gene expression (see above), were stimulated with PHA-PMA and subjected to RT-PCR to investigate the expression of the following genes: IL-6, IL-8, IL-10, TNF- α , GM-CSF and TGF- β 1.

As shown in Fig. 3, all of the clones tested expressed TNF- α , TGF- β 1 and IL-10 mRNA, 6/10 clones (nos 16, 23, 24, 30, 32 and 34) expressed GM-CSF mRNA, 5/10 clones (21, 24, 30, 32, 34) expressed IL-6 mRNA, 5/10 clones (21, 22, 23, 24, 32) displayed IL-8 transcripts (Fig. 3). Although assays to ascertain the presence of the corresponding proteins in culture supernatants were not carried out, these results suggest that *in vivo* activated T cells from SF of pauciarticular JA patients may influence joint inflammation in a complex manner.

DISCUSSION

There is general consensus that T lymphocytes act as initiators of joint inflammation in RA [30,31] by migrating to the affected joints, recognizing peptides deriving from processed antigens and releasing a host of cytokines [32,33]. Such cytokines, in turn, may influence the function of other cell types, such as macrophages, dendritic cells, synoviocytes and neutrophils. Candidate antigens capable of activating synovial T lymphocytes from JA patients are heat shock proteins from Gram-negative bacteria and viral peptides [6–8,34].

In this study, a fraction of SF T cells from patients with oligoarticular JA were found to express activation markers [2–5]. Therefore, such cells were preferentially expanded in the presence of low-dose rIL-2 and cloned. This procedure was not applied to

 $\label{eq:correlation} \begin{array}{l} \mbox{Table 3. Correlation between IFN-γ, IL-2, IL-4 and IL-5 gene expression and release of the corresponding protein by synovial fluid (SF)-derived T cell clones \end{array}$

Clone	IFN-γ		IL-2		IL-4		IL-5	
	Protein	mRNA	Protein	mRNA	Protein	mRNA	Protein	mRNA
16	+	+	+	+	+	+	+	+
19	_	+	_	_	_	_	_	_
21	+	+	_	_	+	+	_	_
22	+	+	+	+	+	+	_	_
23	+	+	_	+	+	+	_	_
24	+	+	+	+	+	+	+	+
27	+	+	+	+	_	_	_	_
29	_	+	_	+	_	_	_	_
32	+	+	_	+	_	+	_	_
34	+	+	+	+	+	+	_	_



Fig. 3. Cytokine gene expression in a panel of synovial fluid of (SF)derived T cell clones. The immunophenotypes of the clones investigated are shown in Table 2. RNA was extracted, reverse transcribed and amplified with pairs of cytokine-specific primers. The expected size of the amplification products is shown on the right.

paired PBMC samples, due to the low number of cells that expressed activation markers. However, the possibility that circulating T lymphocytes contained some IL-2 selectable T cells related to SF T cells cannot be excluded.

The strategy of raising T cell clones after the bulk expansion of *in vitro* activated lymphocytes has advantages as well as limitations. The main advantage is the opportunity of characterizing T cell clones which are predominantly the progeny of cells already activated *in vivo*. A major drawback is that, also under the best culture conditions, the cloning efficiency is limited, and therefore the clones obtained are not fully representative of all the cells present *in vivo*. Furthermore, the possibility that some 'sister' clones originating from *in vivo* clonally expanded T cell populations were raised in this study cannot be ruled out.

Most of the clones raised here were TCR α/β^+ , CD4⁺, but a proportion of them were either TCR α/β^+ , CD8⁺ or TCR γ/δ^+ CD4⁻ CD8⁻. As for the CD4⁺ T cell clones, it can be assumed that they were indeed derived from *in vivo* activated T lymphocytes, since resting CD4⁺ cells never express the CD122 component of the IL-2 receptor in the absence of CD25 [35]. Therefore, the latter

cells cannot mount a proliferative response upon exposure to rIL-2 alone.

In contrast, circulating TCR γ/δ^+ cells [36,37] and a minor subset of TCR α/β^+ , CD8⁺ cells which contains lymphokineactivated killer (LAK) cell precursors [38] express constitutively CD122 in the absence of CD25. This feature allows both cell types to proliferate following *in vitro* treatment with high-dose rIL-2. Thus, although low concentrations of rIL-2 were used in this study, the possibility that some of our TCR γ/δ^+ and TCR α/β^+ , CD8⁺ T cell clones originated from IL-2-responsive LAK precursors cannot be ruled out.

The most striking feature of all the clones obtained from the SF of the different patients was the ability to release huge amounts of IFN- γ irrespective of the immunophenotype. When the IFN- γ /IL-4 ratio from culture supernatants was employed to assign T cell clones to the Th1-type, Th2-type or Th0-type categories, it became apparent that more than half of the clones displayed a Th1-type profile, since they released little or no IL-4 [11–13]. The latter conclusion was strengthened by the observation that most of the clones did not produce IL-5 at all [14]. RT-PCR analysis of selected clones demonstrated that the failure to detect IL-5 in culture supernatants was attributable to the lack of transcription of the corresponding gene.

The Th1-type profile was detected in the majority of TCR α/β^+ , CD8⁺ and TCR γ/δ^+ , CD4⁻, CD8⁻ clones, but only in approximately a half of TCR α/β^+ , CD4⁺ clones. The remaining clones were all classified as Th0-type. The finding that TCR α/β CD8⁺ or TCR γ/δ CD4⁻, CD8⁻ T cell clones displayed patterns of cytokine secretion previously ascribed to CD4⁺ cells only is not surprising in the light of previous results [14,16,39,40].

Studies carried out in humans [41–44] and in experimental animals [45,56] suggest that lymphocytes infiltrating inflamed tissues comprise a mixture of antigen-specific and antigen-nonspecific activated T cells. It is conceivable that a similar scenario applies also to our study. Whatever the mechanism(s) responsible for *in vivo* T cell activation in oligoarticular JA, it may be hypothesized that special stimuli, such as for example IL-12 [47] or the recently cloned IFN- γ -inducing factor (IGIF) [48], trigger IFN- γ overproduction by activated T and NK cells within the inflamed joints [49].

The availability of large amounts of IFN- γ might influence the joint microenvironment in different ways. For example, IFN- γ can activate tissue macrophages to release a wide spectrum of cytokines and inflammatory molecules [50]. Furthermore, IFN- γ up-regulates the surface expression of HLA-class I and II antigens, thus enhancing the antigen-presenting cell (APC) capabilities of various cell types [51]. Finally, IFN- γ may favour the differentiation of Th1-type cells and, in the meanwhile, inhibit the generation of Th-2-type cells [52–54].

An alternative hypothesis to explain the enrichment for IFN- γ producing T cell clones in our study is that they were selected by the system for expansion and cloning of *in vivo* activated T cells. This hypothesis is, however, unlikely, since recent studies have disclosed a Th1-type pattern both in the synovial membrane [20] and in T cell clones derived from the SF [19] or membrane [18–21] of RA patients.

In principle, a final possibility is that IFN- γ overproduction by SF T cells resulted from a generalized abnormality of the patient immune system. This hypothesis, which is made unlikely by the failure to detect circulating activated T cells in our patients, is not supported by the results of a study carried out recently in adult RA patients, where IFN- γ overproduction was observed selectively in synovial T lymphocytes compared with mitogen-activated peripheral blood T cell clones.

In order to gain more insight into the potential pathogenic role played *in vivo* by activated T cells, the expression of pro- and antiinflammatory cytokines in a selected panel of T lymphocyte was investigated. These experiments demonstrated that most of the clones tested expressed the transcripts of inflammatory cytokines such as GM-CSF, TNF- α , IL-6 or IL-8. This finding supports the hypothesis that *in vivo* activated SF T cells, from which the clones were derived, may be involved in the pathogenesis of tissue damage. Conversely, the same clones were found to express the genes of IL-10 and TGF- β 1, two cytokines which display potent immunosuppressive and anti-inflammatory properties.

In conclusion, these results provide the first demonstration that SF T cell clones from patients with oligoarticular JA display predominantly Th1/Th0 patterns of cytokine secretion. Further studies are warranted to better define the actual role played by *in vivo* activated T cells in the pathogenesis of synovial tissue damage.

ACKNOWLEDGMENTS

We would like to thank Professor Manlio Ferrarini and Professor Patricia Woo for helpful suggestions in the manuscript preparation.

REFERENCES

- 1 Fink CW and the Task Force for Classification Criteria. Proposal the development of classification for idiopathic arthritides of childhood. J Rheumatol 1995; 22:1566–9.
- 2 Forre O, Dobloug JH, Natvig JB. Augmented numbers of HLA-DRpositive T-lymphocytes in the synovial fluid and synovial tissue of patients with rheumatoid arthritis and juvenile rheumatoid arthritis. Scand J Immunol 1982; 15:227–31.
- 3 Konttinen YT, Bergroth V, Kunnamo I, Haapasaari J. The value of biopsy in patients with monoarticular juvenile rheumatoid arthritis of recent onset. Arthritis Rheum 1986; 29:47–53.
- 4 De Maria A, Malnati M, Moretta A *et al.* CD3⁺ 4⁻8⁻WT31⁻ (T cell receptor γ^+) cells and other unusual phenotypes are frequently detected among spontaneously interleukin2-responsive T lymphocytes present in the joint fluid in juvenile rheumatoid arthritis. A clonal analysis. Eur J Immunol 1987; **17**:1815–9.
- 5 Bergroth V, Konttinen YT, Pelkonen P, Haapala M, Haapasaari J, Nordstrom D, Kunnamo I, Friman C. Synovial fluid lymphocytes in different subtypes of juvenile rheumatoid arthritis. Arthritis Rheum 1988; **31**:780–3.
- 6 Silverman ED, Isacovics B, Petsche D, Laxer RM. Synovial fluid cells in juvenile arthritis: evidence of selective T cell migration to inflamed tissue. Clin Exp Immunol 1993; **91**:90–95.
- 7 Life P, Hassel A, Williams S, Young S, Bacon P, Southwood T, Gaston JSH. Response to Gram-negative enteric bacterial antigens by synovial T cells from patients with juvenile chronic arthritis: recognition of heat shock protein HPS60. J Rheumatol 1993; 20:1388–96.
- 8 Albani S, Ravelli A, Massa M, De Benedetti F, Andree G, Roudier J, Martini A, Carson DA. Immune response to the *Escherichia coli* dnaJ heat shock protein in juvenile rheumatoid arthritis and their correlation with disease activity. J Pediatr 1994; **124**:561–5.
- 9 de Graeff-Meeder ER, van Eden W, Rijkers GT et al. Juvenile chronic arthritis: T cell reactivity to human HSP60 in patient with a favourable course of arthritis. J Clin Invest 1995; 95:934–40.
- 10 Eberhard BA, Laxer RM, Andersson U, Silverman ED. Local synthesis of both macrophage and T cell cytokines by synovial fluid cells from

children with juvenile rheumatoid arthritis. Clin Exp Immunol 1994; 96:260-6.

- 11 Mosmann TR, Cherwienski H, Bond MV, Giedlin MA, Coffman R. Two types of murine helper T cells clones. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136:2348–57.
- 12 Del Prete GF, De Carli M, Mastromauro C, Biagiotti R, Macchia S, Falagiani P, Ricci M, Romagnani S. Purified protein derivative of *Mycobacterium tuberculosis* and excretory-secretory antigen(s) of *Toxocara canis* expand *in vitro* human T cells with stable and opposing (type I T helper and type II T helper) profiles of cytokine production. J Clin Invest 1991; 8:346–50.
- 13 Haanen JBAG, deWaal Malefijt R, Res PCM, Kraakman EM, Ottenhoff THM, deVries RRP, Spits H. Selection of human T helper type 1-like T cell subset in mycobacteria. J Exp Med 1991; 174:583–92.
- 14 Salgame P, Abrams JS, Clayberger C, Goldstein H, Convi J, Modlin RL, Bloom BR. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 1991; 254:279–81.
- 15 Firestein GS, Roeder WD, Laxer JA *et al*. A new murine CD4⁺ T cell subset with an unrestricted cytokine profile. J Immunol 1989; **143**:518– 25.
- 16 Paliard X, de Waal Malefyt R, Yssel H, Blanchard D, Chretien I, Abrams J, de Vries J, Spits H. Simultaneous production of IL-2, IL-4, and IFN- γ by activated human CD4⁺ and CD8⁺ T cell clones. J Immunol 1988; **141**:849–55.
- 17 Street NE, Schumacher JH, Fong TAT, Bass H, Fiorentino D, Leverah JA, Mosman TR. Heterogeneity of mouse helper T cells: evidence from bulk cultures and limiting dilution cloning for precursors of Th1 and Th2 cells. J Immunol 1990; 144:1629–39.
- 18 Miltenburg AMM, Van Laar JM, De Kuiper R, Daha MR, Breedveld FC. T cells cloned from human rheumatoid synovial membrane functionally represent the Th1 subset. Scand J Immunol 1992; 35: 603–10.
- 19 Quayle AJ, Chomarat P, Miossec P, Kjeldsen-Kragh J, Forre O, Natvig JB. Rheumatoid inflammatory T-cell clones express mostly Th1 but also Th2 and mixed (Th0-like) cytokine patterns. Scand J Immunol 1993; 38:75–82.
- 20 Simon AK, Seipelt E, Sieper J. Divergent T cell cytokine pattern in inflammatory arthritis. Proc Natl Acad Sci USA 1994; 91:8562–6.
- 21 Choen SBA, Katsikis PD, Chu CQ, Thomssen H, Webb LMC, Maini RN, Londei M, Feldmann M. High level of interleukin 10 production by the activated T cell population within the rheumatoid synovial membranes. Arthritis Rheum 1995; 38:946–52.
- 22 Canessa A, Pistoia V, Roncella S, Merli A, Melioli G, Terragna A, Ferrarini M. An *in vitro* model for Toxoplasma infection in man. Interaction between CD4⁺ monoclonal T cells and macrophages results in killing of trophozoites. J Immunol 1988; **140**:3580–8.
- 23 Prigione I, Facchetti P, Lanino E, Garaventa A, Pistoia V. Clonal analysis of peripheral blood lymphocytes from three patients with advanced neuroblastoma receiving recombinant interleukin-2 and interferon α . Cancer Immunol Immunother 1993; **37**:40–46.
- 24 Gillis SM, Ferm MM, Ou W, Smith KA. T cell growth factor: parameters of production and quantitative microsassay for activity. J Immunol 1978; 120:2027–31.
- 25 Rolink AG, Melchers F, Palacios R. Monoclonal antibodies reactive with the mouse interleukin 5 receptor. J Exp Med 1989; 1693–701.
- 26 Prigione I, Facchetti P, Ghiotto F, Tasso P, Pistoia V. *Toxoplasma gondii*-specific CD4⁺ T cell clones from healthy, latently infected humans display a Th0 profile of cytokine secretion. Eur J Immunol 1995; 25:1290–305.
- 27 Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156–9.
- 28 Yamamura M, Uyemura K, Deans RJ, Weimberg K, Rea TH, Bloom BR, Modlin RL. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science 1991; 254:277–9.
- 29 Hovdenes J, Gaudrenack G, Kvien TK, Egeland T. Expression of
- © 1997 Blackwell Science Ltd, Clinical and Experimental Immunology, 109:4-11

activation markers on CD4⁺ and CD8⁺ from synovial fluid, synovial tissue and peripheral blood of patients with inflammatory arthritis. Scan J Immunol 1989; **29**:631–9.

- 30 Firestein GS, Zvaifler NJ. How important are T cells in chronic rheumatoid synovitis? Arthritis Rheum 1990; **33**:768–73.
- 31 Panayi GS, Lachburry JS, Kingsley JS. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum 1992; 35:729–36.
- 32 Buchan G, Barret K, Fujita T, Taniguchi T, Maini R, Feldman M. Detection of activated T cell products in the rheumatoid joint using cDNA probes to interleukin-2 (IL-2) receptor and IFN- γ . Clin Exp Immunol 1988; **71**:295–301.
- 33 Firestein GS, Alvaro-Garcia JM, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 1990; 144:3347-53.
- 34 Albani S. Infection and molecular mimicry in autoimmune diseases of childhood. Clin Exp Rheum 1994; **12**(Suppl. 10):35–41.
- 35 Tsudo M, Kitamura F, Miyasaka M. Characterization of the interleukin 2 receptor β chain using three distinct monoclonal antibodies. Proc Natl Acad Sci USA 1989; 86:1982–8.
- 36 Moingeon P, Jitsukawa S, Faure F *et al*. A γ-chain complex forms a functional receptor on cloned human lymphocytes with natural killerlike activity. Nature 1987; **325**:723–6.
- 37 Ferrini S, Bottino C, Biassoni R, Poggi A, Sekaly RP, Moretta L, Moretta A. Characterization of CD3⁺, CD4⁻, CD8⁻ clones expressing the putative T cell receptor γ gene product. J Exp Med 1987; **166**: 277–82.
- 38 Dianzani U, Zarcone D, Pistoia V, Grossi CE, Pileri A, Massaia M, Ferrarini M. CD8⁺ CD11b⁺ peripheral blood T lymphocytes contain lymphokine-activated killer cell precursors. Eur J Immunol 1989; 19: 1037–44.
- 39 Erard F, Wild MT, Garcia-Sanx JA, Le Gros G. Switch of CD8 T cells to non-cytolitic CD8⁻ CD4⁻ cells that make Th2 cytokines and help B cells. Science 1993; 260:1802–5.
- 40 Chomarat P, Kjeldsen-Kragh J, Quayle AJ, Natvig JB, Miossec P. Different cytokine production profile of γδ T cell clones: relation to inflammatory arthritis. Eur J Immunol 1994; 24:2087–91.
- 41 De Maria AF, Malnati MS, Poggi A, Pende D, Cottafava F, Moretta L. Clonal analysis of joint fluid lymphocytes in patients with juvenile chronic arthritis. J Rheumatol 1990; 17:1073–8.

- 42 Fujiwara H, Tsuyuguchi I. Frequency of tuberculin-reactive T lymphocytes in pleural fluid and blood from patients with tuberculous pleurisy. Chest 1986; **89**:530–2.
- 43 Sun J, Link T, Olsson H, Xiao BG, Anderson G, Ekre HP, Linington C, Diener P. T and B cell responses to myelin-oligodendrocyte glycoprotein in multiple sclerosis. J Immunol 1991; 146:1490–5.
- 44 Sieper J, Braun J, Wu P, Kingsley G. T cells are responsible for the enhanced synovial cellular immune response to triggering antigen in reactive arthritis. Clin Exp Immunol 1993; 91:96–102.
- 45 Grossman Z, Paul WE. Adaptive cellular interaction in the immune system: the tunable activation thereshold and the significance of subthereshold responses. Proc Natl Acad Sci USA 1992; 89:10365–9.
- 46 Carding SR, Allan W, McMickle A, Doherty P. Activation of cytokine genes in T cells during primary and secondary murine influenza. J Exp Med 1993; 177:475–80.
- 47 Kobayashi M, Fitz L, Ryan M *et al.* Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes. J Exp Med 1990; **170**:827– 45.
- 48 Okamura H, Tsusui H, Komatsu T *et al.* Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 1995; 378:88–91.
- 49 Manetti R, Parronchi P, Giudizi MG, Piccinini MP, Maggi E, Trinchieri G, Romagnani S. Natural killer cell stimulatory factor (interleukin 12 [IL12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4 producing Th cells. J Exp Med 1993; 177:1119–204.
- 50 Nacy CA, Maltzer MS. T cell-mediated activation of macrophages. Curr Opin Immunol 1991; 3:330–5.
- 51 Wong GHW, Clark-Lewis I, McKimm-Brechkin JL, Harris AW, Schrader JW. Interferon-γ induces enhanced expression of Ia and H-2 antigens on B lymphoid, macrophage and myeloid cell lines. J Immunol 1983; 131:788–93.
- 52 Gajewski TF, Fitch FW. Anti-proliferative effect on IFN- γ in immune regulation. I. IFN- γ inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J Immunol 1988; **140**:4245–52.
- 53 Maggi E, Parronchi P, Manetti R *et al*. Reciprocal regulatory effects of IFN-γ and IL4 on the *in vitro* development of human Th1 and Th2 clones. J Immunol 1992; **148**:2142–7.
- 54 Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Science 1996; 383:787–93.